<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>XIFAXANÂ - rifaximinÂ tabletÂ </strong><br>Physicians Total Care, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use XIFAXAN safely and
        effectively. See full prescribing information for XIFAXAN.<br><br>XIFAXANÂ®
        (rifaximin) Tablets<br>Initial U.S. Approval: 2004<br><br>To reduce the development of
        drug-resistant bacteria and maintain the effectiveness of XIFAXAN and other antibacterial
        drugs, XIFAXAN should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or
        strongly suspected to be caused by bacteria.</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">XIFAXAN is a rifamycin antibacterial indicated
                                    for: </p>
<ul class="Disk">
<li>The treatment of patients (â‰¥ 12 years of age)
                                        with travelersâ€™ <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (TD) caused by
                                        noninvasive <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Escherichia coli
                                            </span>(<a href="#LINK_25dde72a-07e4-4de2-aee8-34599b73de67">1.1</a>)</li>
<li>Reduction in risk of overt <span class="product-label-link" type="condition" conceptid="4029488" conceptname="Hepatic encephalopathy">hepatic encephalopathy</span> (HE)
                                        recurrence in patients â‰¥ 18 years of age
                                            (<a href="#LINK_a6be46f8-06a2-4e5c-a8cc-7d91212b12d0">1.2</a>)</li>
</ul>
<p class="Highlighta"><span class="Underline">Limitations of Use</span> </p>
<ul class="Disk"><li>TD: Do not use in patients with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> complicated by
                                        <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or blood in the stool or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> due to pathogens
                                        other than <span class="Italics">Escherichia coli
                                            </span>(<a href="#LINK_25dde72a-07e4-4de2-aee8-34599b73de67">1.1</a>)</li></ul>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disk">
<li>Travelersâ€™ <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>: One 200 mg tablet taken
                                        orally three times a day for 3 days, with or without food
                                            (<a href="#LINK_e1e7a203-300f-4465-a6ec-6df7d9ab6c16">2.1</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4029488" conceptname="Hepatic encephalopathy">Hepatic encephalopathy</span>: One 550 mg tablet taken orally two
                                        times a day, with or without food (<a href="#LINK_aeb50897-9ef2-41f7-a2d3-24daa2acd768">2.2</a>)</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disk"><li>200 mg and 550 mg tablets (<a href="#LINK_8d048f17-cb8a-4446-8668-534c3e7506cb">3</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">History of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to rifaximin, rifamycin
                                    antimicrobial agents, or any of the components of XIFAXAN
                                        (<a href="#LINK_a3c8f9bf-4348-4198-957e-58df6dbef375">4.1</a>) Â  </p></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disk">
<li>Travelersâ€™ <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> Not Caused by <span class="Italics">E.
                                                coli</span>: XIFAXAN was not effective
                                        in <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> complicated by <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and/or blood in the stool
                                        or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> due to pathogens other than <span class="Italics">E.
                                                coli</span>. If <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> symptoms get
                                        worse or persist for more than 24-48 hours, discontinue
                                        XIFAXAN and consider alternative antibiotics (<a href="#LINK_5b41e799-d757-48f5-b0ac-6b1fbd96c712">5.1</a>)</li>
<li>
<span class="Italics">Clostridium
                                        difficile</span>-Associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>: Evaluate
                                        if <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> occurs after therapy or does not improve or
                                        worsens during therapy (<a href="#LINK_63662187-64c2-4919-9db0-ac306c8f84dd">5.2</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>: Use with caution in patients with
                                        severe (Child-Pugh C) <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (<a href="#LINK_53c39909-6b02-4e98-8a48-dc12b43bdb37">5.4</a>, <a href="#LINK_e20a5a41-ac1b-4bee-8661-44551f389f05">8.7</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul class="Disk">
<li>Most common adverse reactions in travelersâ€™ <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (â‰¥ 5%):Â  <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4279274" conceptname="Rectal tenesmus">rectal tenesmus</span>, <span class="product-label-link" type="condition" conceptid="4216708" conceptname="Urgent desire for stool">defecation urgency</span> and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (<a href="#LINK_2c9c0b95-8b7e-4f65-a83a-38a684229c9e">6.1</a>)
</li>
<li>Most common adverse reactions in HE (â‰¥ 10%): <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (<a href="#LINK_2c9c0b95-8b7e-4f65-a83a-38a684229c9e">6.1</a>)</li>
</ul>
<p class="Highlighta"><span class="Bold">To report suspected adverse reactions, contact Salix Pharmaceuticals at 1-800-508-0024 and www.Salix.com or FDA at 1-800-FDA-1088 or </span><span class="Bold"><span class="Italics">www.fda.gov/medwatch</span></span> </p>
</div>
<div></div>
<div></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disk">
<li>Pregnancy: Based on animal data, may cause fetal harm
                                            (<a href="#LINK_1978d785-e1b1-46b8-84c6-84003698a307">8.1</a>)</li>
<li>Nursing Mothers: Discontinue nursing or drug, taking into
                                        account the importance of the drug to the mother (<a href="#LINK_890b1e88-8386-45f8-81cb-e48c58ab1744">8.3</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 12/2011</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Travelersâ€™ <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></a></h2>
<h2><a href="#section-1.2" class="toc">1.2 <span class="product-label-link" type="condition" conceptid="4029488" conceptname="Hepatic encephalopathy">Hepatic Encephalopathy</span></a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Dosage for Travelersâ€™ <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Dosage for <span class="product-label-link" type="condition" conceptid="4029488" conceptname="Hepatic encephalopathy">Hepatic Encephalopathy</span></a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h2><a href="#section-4.1" class="toc">4.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></a></h2>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Travelersâ€™ <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> Not Caused by <span class="Italics">Escherichia
                                coli</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="Italics">Clostridium difficile</span>-Associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Development of Drug Resistant Bacteria</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Severe (Child-Pugh C) <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Studies Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-11.3" class="toc">12.4 Microbiology</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Travelersâ€™ <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></a></h2>
<h2><a href="#section-13.2" class="toc">14.2 <span class="product-label-link" type="condition" conceptid="4029488" conceptname="Hepatic encephalopathy">Hepatic Encephalopathy</span></a></h2>
<h1><a href="#section-14" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-15.1" class="toc"></a></h2>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-16.1" class="toc">17.1 Persistent <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></a></h2>
<h2><a href="#section-16.2" class="toc">17.2 <span class="Italics">Clostridium difficile</span>-Associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_dfbc66a2-cbe8-498e-a7e6-1688402aad30"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">Â Â Â Â Â Â Â Â To
                            reduce the development of drug-resistant bacteria and maintain the
                            effectiveness of XIFAXAN and other antibacterial drugs, XIFAXAN when
                            used to treat <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> should be used only to treat or prevent
                            <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by
                            susceptible bacteria.Â  When culture and susceptibility
                            information are available, they should be considered in selecting or
                            modifying antibacterial therapy. Â In the absence of such data,
                            local epidemiology and susceptibility patterns may contribute to the
                            empiric selection of therapy.</p>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_25dde72a-07e4-4de2-aee8-34599b73de67"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Travelersâ€™ <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></h2>
<p class="First">Â Â Â Â Â Â Â Â XIFAXAN
                                    200 mg is indicated for the treatment of patients (â‰¥
                                    12 years of age) with travelersâ€™ <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> caused by
                                    noninvasive <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Escherichia coli
                                        [</span><span class="Italics">see
                                        Warnings</span>Â <span class="Italics">and
                                            Precautions (<a href="#LINK_9638a9a0-02bc-4acb-94c6-985c1605d6e1">5</a>)</span>, <span class="Italics">Clinical
                                            Pharmacology (<a href="#LINK_374fa7d7-132d-43ba-986a-fcbf9b68ea93">12.4</a>)</span> and<span class="Italics">
                                            Clinical</span>Â <span class="Italics">Studies</span>Â <span class="Italics">(<a href="#LINK_fd945abe-1e7a-44d6-ab02-a58cb344efef">14.1</a>)]</span>.</p>
<p>Â Â Â Â Â Â Â Â <span class="Italics"><span class="Underline">Limitations of Use</span></span></p>
<p>Â Â Â Â Â Â Â Â XIFAXAN
                                    should not be used in patients with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> complicated by
                                    <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or blood in the stool or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> due to pathogens other
                                    than <span class="Italics">Escherichia coli</span>.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_a6be46f8-06a2-4e5c-a8cc-7d91212b12d0"></a><a name="section-1.2"></a><p></p>
<h2>1.2 <span class="product-label-link" type="condition" conceptid="4029488" conceptname="Hepatic encephalopathy">Hepatic Encephalopathy</span></h2>
<p class="First">Â Â Â Â Â Â Â Â XIFAXAN 550 mg is indicated for reduction in risk of overt <span class="product-label-link" type="condition" conceptid="4029488" conceptname="Hepatic encephalopathy">hepatic encephalopathy</span> (HE) recurrence in patients â‰¥ 18 years of age. </p>
<p>Â Â Â Â Â Â Â Â In the trials of XIFAXAN for HE, 91% of the patients were using lactulose concomitantly. Differences in the treatment effect of those patients not using lactulose concomitantly could not be assessed.</p>
<p>Â Â Â Â Â Â Â Â XIFAXAN has not been studied in patients with MELD (Model for End-Stage Liver Disease) scores &gt; 25, and only 8.6% of patients in the controlled trial had MELD scores over 19.Â  There is increased systemic exposure in patients with more severe hepatic dysfunction <span class="Italics">[see Warnings and Precautions (<a href="#LINK_53c39909-6b02-4e98-8a48-dc12b43bdb37">5.4</a>), Use in Specific Populations (<a href="#LINK_e20a5a41-ac1b-4bee-8661-44551f389f05">8.7</a>), Clinical Pharmacology (<a href="#LINK_7cafd3ea-e566-485d-879e-2864760577ad">12.3</a>)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_5b0368f0-663d-4a82-a3a6-c90548e310e2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_e1e7a203-300f-4465-a6ec-6df7d9ab6c16"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Dosage for Travelersâ€™ <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></h2>
<p class="First">Â Â Â Â Â Â Â Â The
                                    recommended dose of XIFAXAN is one 200 mg tablet taken orally
                                    three times a day for 3 days.Â  XIFAXAN can be
                                    administered orally, with or without food <span class="Italics">[see
                                            Clinical Pharmacology (<a href="#LINK_7cafd3ea-e566-485d-879e-2864760577ad">12.3</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="LINK_aeb50897-9ef2-41f7-a2d3-24daa2acd768"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Dosage for <span class="product-label-link" type="condition" conceptid="4029488" conceptname="Hepatic encephalopathy">Hepatic Encephalopathy</span></h2>
<p class="First">Â Â Â Â Â Â Â Â The recommended dose of XIFAXAN is one 550 mg tablet taken orally two times a day, with or without food<span class="Italics">[see Clinical Pharmacology (<a href="#LINK_7cafd3ea-e566-485d-879e-2864760577ad">12.3</a>)].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="LINK_8d048f17-cb8a-4446-8668-534c3e7506cb"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Â Â Â Â Â Â Â Â XIFAXAN
                            is a pink-colored biconvex tablet and is available in the following
                            strengths:</p>
<ul class="Disk">
<li>200 mg â€“ a round tablet debossed with
                                â€œSxâ€? on one side. </li>
<li>550 mg â€“ an oval tablet debossed with
                                â€œrfxâ€? on one side.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_0167646e-784a-4290-9814-5a55e50c6958"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_a3c8f9bf-4348-4198-957e-58df6dbef375"></a><a name="section-4.1"></a><p></p>
<h2>4.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First">Â Â Â Â Â Â Â Â XIFAXAN is contraindicated in patients with a
                                    <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to rifaximin, any of the rifamycin
                                    antimicrobial agents, or any of the components in
                                    XIFAXAN.Â  <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> have included
                                    <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span>, and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>
                                        <span class="Italics">[see Adverse Reactions (</span><span class="Italics"><a href="#LINK_cdc36101-f824-4433-92a5-05aa2933d387">6.2</a></span><span class="Italics">)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="LINK_9638a9a0-02bc-4acb-94c6-985c1605d6e1"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="43685-7">
<a name="LINK_5b41e799-d757-48f5-b0ac-6b1fbd96c712"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Travelersâ€™ <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> Not Caused by <span class="Italics">Escherichia
                                coli</span>
</h2>
<p class="First">Â Â Â Â Â Â Â Â XIFAXAN
                                    was not found to be effective in patients with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>
                                    complicated by <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and/or blood in the stool or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> due
                                    to pathogens other than <span class="Italics">Escherichia
                                        coli</span>. </p>
<p>Â Â Â Â Â Â Â Â Discontinue
                                    XIFAXAN if <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> symptoms get worse or persist more than
                                    24-48 hours and alternative antibiotic therapy should be
                                    considered.</p>
<p>Â Â Â Â Â Â Â Â XIFAXAN
                                    is not effective in cases of travelersâ€™ <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> due
                                    to <span class="Italics">Campylobacter jejuni</span>. The
                                    effectiveness of XIFAXAN in travelersâ€™ <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> caused
                                    by <span class="Italics">Shigella </span>spp. and <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span>
                                        </span>spp. has not been proven. XIFAXAN should
                                    not be used in patients where <span class="Italics">Campylobacter
                                            jejuni</span>, <span class="Italics">Shigella
                                        </span>spp., or <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span>
                                        </span>spp. may be suspected as causative
                                    pathogens.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="LINK_63662187-64c2-4919-9db0-ac306c8f84dd"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="Italics">Clostridium difficile</span>-Associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></h2>
<p class="First"><span class="Italics">Â Â Â Â Â Â Â Â Clostridium
                                            difficile</span>-associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD)
                                    has been reported with use of nearly all antibacterial agents,
                                    including XIFAXAN, and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>
                                    to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.Â  Treatment with antibacterial agents
                                    alters the normal flora of the colon which may lead to
                                    overgrowth of <span class="Italics">C.
                                    difficile</span>.</p>
<p><span class="Italics">Â Â Â Â Â Â Â Â C.
                                            difficile</span> produces toxins A and B
                                    which contribute to the development of CDAD.Â 
                                    Hypertoxin producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">C.
                                        difficile</span> cause increased morbidity and
                                    mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to
                                    antimicrobial therapy and may require colectomy.Â  CDAD
                                    must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>
                                    following antibiotic use.Â  Careful medical history is
                                    necessary since CDAD has been reported to occur over two months
                                    after the administration of antibacterial agents.</p>
<p>Â Â Â Â Â Â Â Â If
                                    CDAD is suspected or confirmed, ongoing antibiotic use not
                                    directed against <span class="Italics">C. difficile</span>
                                    may need to be discontinued.Â  Appropriate fluid and
                                    electrolyte management, protein supplementation, antibiotic
                                    treatment of <span class="Italics">C. difficile</span>,
                                    and surgical evaluation should be instituted as clinically
                                    indicated.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="LINK_dd01149c-6a14-4152-a287-7aebe32d6e2d"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Development of Drug Resistant Bacteria</h2>
<p class="First">Â Â Â Â Â Â Â Â Prescribing XIFAXAN for travelersâ€™ <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> in
                                    the absence of a proven or strongly suspected bacterial
                                    <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide
                                    benefit to the patient and increases the risk of the development
                                    of drug-resistant bacteria.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="LINK_53c39909-6b02-4e98-8a48-dc12b43bdb37"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Severe (Child-Pugh C) <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Â Â Â Â Â Â Â Â There is increased systemic exposure in patients with
                                    severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Animal toxicity studies did not
                                    achieve systemic exposures that were seen in patients with
                                    severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. The clinical trials were limited to
                                    patients with MELD scores &lt;25. Therefore, caution should
                                    be exercised when administering XIFAXAN to patients with severe
                                    <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh C)</p>
<span class="Italics">[see Use in Specific Populations
                                            (<a href="#LINK_e20a5a41-ac1b-4bee-8661-44551f389f05">8.7</a>), Nonclinical Toxicology (<a href="#LINK_ae332060-9273-4ded-ad1a-47b8746c493c">13.2</a>) and Clinical Studies (<a href="#LINK_1d3a2440-6a39-4aae-bd08-e53925c4a095">14.2</a>)]</span>.
                            </div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_b1a51dcb-a309-4626-b310-93905fca7594"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_2c9c0b95-8b7e-4f65-a83a-38a684229c9e"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Studies Experience</h2>
<p class="First">Â Â Â Â Â Â Â Â Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<br><p>Â Â Â Â Â Â Â Â <span class="Italics"><span class="Underline">Travelersâ€™ <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></span></span></p>
<p>Â Â Â Â Â Â Â Â The safety of XIFAXAN 200 mg taken three times a day was evaluated in patients with travelersâ€™ <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> consisting of 320 patients in two placebo-controlled clinical trials with 95% of patients receiving three or four days of treatment with XIFAXAN. The population studied had a mean age of 31.3 (18-79) years of which approximately 3% were â‰¥ 65 years old, 53% were male and 84% were White, 11% were Hispanic. </p>
<p>Â Â Â Â Â Â Â Â Discontinuations due to adverse reactions occurred in 0.4% of patients.Â  The adverse reactions leading to discontinuation were <span class="product-label-link" type="condition" conceptid="4289517" conceptname="Loss of taste">taste loss</span>, <span class="product-label-link" type="condition" conceptid="4008089" conceptname="Dysentery">dysentery</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight decrease</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and nasal passage irritation. </p>
<p>Â Â Â Â Â Â Â Â All adverse reactions for XIFAXAN 200 mg three times daily that occurred at a frequency â‰¥ 2% in the two placebo-controlled trials combined are provided in Table 1. (These include adverse reactions that may be attributable to the underlying disease.)</p>
<a name="idb296700-abeb-4b6d-875b-a5a4ef0ebaa7"></a><table>
<caption><span>Table 1. All Adverse Reactions With an Incidence â‰¥2% Among Patients Receiving XIFAXAN Tablets, 200 mg Three Times Daily, in Placebo-Controlled Studies</span></caption>
<col>
<col>
<col>
<thead>
<tr class="First">
<th class="Botrule Lrule Rrule Toprule" rowspan="2">
<span class="Bold">MedDRA Preferred Term</span><br>
</th>
<th class="Botrule Lrule Rrule Toprule" align="center" colspan="2">
<span class="Bold">Number (%) of PatientsÂ </span><br>
</th>
</tr>
<tr class="Last">
<th class="Botrule Lrule Rrule Toprule" align="center">
<span class="Bold"><span class="Bold">XIFAXAN<br>Tablets, 600Â mg/day</span><br><span class="Bold">(NÂ =Â 320)</span></span><br>
</th>
<th class="Botrule Lrule Rrule Toprule" align="center">
<span class="Bold"><br>Placebo</span><br><span class="Bold">N = 228</span><br>
</th>
</tr>
</thead>
<tfoot><tr class="First Last"><td>Â 
<p class="First">*NOS: Not otherwise specified</p>
</td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule">Â 
<p class="First"><span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">36 (11%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">45 (20%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â 
<p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">31 (10%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">21 (9%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â 
<p class="First"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span> NOS<span class="Sup">*</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">23 (7%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">23 (10%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â 
<p class="First"><span class="product-label-link" type="condition" conceptid="4279274" conceptname="Rectal tenesmus">Rectal Tenesmus</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">23 (7%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">20 (9%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â 
<p class="First"><span class="product-label-link" type="condition" conceptid="4216708" conceptname="Urgent desire for stool">Defecation Urgency</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">19 (6%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">21 (9%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â 
<p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">17 (5%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">19 (8%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â 
<p class="First"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">12 (4%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">8 (4%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â 
<p class="First"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">10 (3%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">10 (4%)</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule">Â 
<p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> NOS</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">7 (2%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">4 (2%)</p>
</td>
</tr>
</tbody>
</table>
<p>Â Â Â Â Â Â Â Â The following adverse reactions, presented by body system, have also been reported in &lt;2% of patients taking XIFAXAN in the two placebo-controlled clinical trials where the 200 mg tablet was taken three times a day for travelersâ€™ <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.Â  The following includes adverse reactions regardless of causal relationship to drug exposure.</p>
<p><span class="Italics">Â Â Â Â Â Â Â Â Blood and Lymphatic System Disorders:</span> <span class="product-label-link" type="condition" conceptid="320074" conceptname="Lymphocytosis">Lymphocytosis</span>, <span class="product-label-link" type="condition" conceptid="434910" conceptname="Monocytosis">monocytosis</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span></p>
<p><span class="Italics">Â Â Â Â Â Â Â Â Ear and Labyrinth Disorders:</span> <span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">Ear pain</span>, <span class="product-label-link" type="condition" conceptid="30284" conceptname="Motion sickness">motion sickness</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span></p>
<p><span class="Italics">Â Â Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">Abdominal distension</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> NOS, <span class="product-label-link" type="condition" conceptid="4010026" conceptname="Pharyngeal dryness">dry throat</span>, <span class="product-label-link" type="condition" conceptid="437671" conceptname="Abnormal feces">fecal abnormality</span> NOS, <span class="product-label-link" type="condition" conceptid="4090111" conceptname="Gingival disease">gingival disorder</span> NOS, <span class="product-label-link" type="condition" conceptid="4288544" conceptname="Inguinal hernia">inguinal hernia</span> NOS, <span class="product-label-link" type="condition" conceptid="4039954" conceptname="Cheilosis">dry lips</span>, <span class="product-label-link" type="condition" conceptid="4152197" conceptname="Stomach ache">stomach discomfort</span></p>
<p><span class="Italics">Â Â Â Â Â Â Â Â General Disorders and Administration Site Conditions:</span> <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> NOS, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span></p>
<p><span class="Italics">Â Â Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span>:</span> <span class="product-label-link" type="condition" conceptid="4008089" conceptname="Dysentery">Dysentery</span> NOS, <span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory tract infection</span> NOS, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span> NOS</p>
<p><span class="Italics">Â Â Â Â Â Â Â Â Injury and <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">Poisoning</span>:</span> Sunburn</p>
<p><span class="Italics">Â Â Â Â Â Â Â Â Investigations:</span> <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">Aspartate aminotransferase</span> increased, <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">blood in stool</span>, <span class="product-label-link" type="condition" conceptid="437038" conceptname="Blood in urine">blood in urine</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight decreased</span></p>
<p><span class="Italics">Â Â Â Â Â Â Â Â Metabolic and Nutritional Disorders:</span> <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span></p>
<p><span class="Italics">Â Â Â Â Â Â Â Â Musculoskeletal, Connective Tissue, and <span class="product-label-link" type="condition" conceptid="75909" conceptname="Disorder of bone">Bone Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasms</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="24134" conceptname="Neck pain">neck pain</span></p>
<p><span class="Italics">Â Â Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">Abnormal dreams</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> NOS, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="4289517" conceptname="Loss of taste">loss of taste</span></p>
<p><span class="Italics">Â Â Â Â Â Â Â Â Psychiatric Disorders: </span><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></p>
<p><span class="Italics">Â Â Â Â Â Â Â Â Renal and Urinary Disorders:</span> <span class="product-label-link" type="condition" conceptid="435080" conceptname="Biliuria">Choluria</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>, <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span></p>
<p><span class="Italics">Â Â Â Â Â Â Â Â Respiratory, Thoracic, and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span> NOS, nasal passage irritation, <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, pharyngolaryngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span> NOS, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span> </p>
<p><span class="Italics">Â Â Â Â Â Â Â Â Skin and Subcutaneous Tissue Disorders:</span> <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">Clamminess</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> NOS, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating increased</span></p>
<p><span class="Italics">Â Â Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">Hot flashes</span> NOS</p>
<p>Â Â Â Â Â Â Â Â <span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4029488" conceptname="Hepatic encephalopathy">Hepatic Encephalopathy</span></span></span></p>
<p>Â Â Â Â Â Â Â Â The data described below reflect exposure to XIFAXAN 550 mg in 348 patients, including 265 exposed for 6 months and 202 exposed for more than a year (mean exposure was 364 days).Â  The safety of XIFAXAN 550 mg taken two times a day for reducing the risk of overt <span class="product-label-link" type="condition" conceptid="4029488" conceptname="Hepatic encephalopathy">hepatic encephalopathy</span> recurrence in adult patients was evaluated in a 6-month placebo-controlled clinical trial (n = 140) and in a long term follow-up study (n = 280).Â  The population studied had a mean age of 56.26 (range: 21-82) years; approximately 20% of the patients were â‰¥ 65 years old, 61% were male, 86% were White, and 4% were Black.Â  Ninety-one percent of patients in the trial were taking lactulose concomitantly. All adverse reactions that occurred at an incidence â‰¥ 5% and at a higher incidence in XIFAXAN 550 mg-treated subjects than in the placebo group in the 6-month trial are provided in Table 2. (These include adverse events that may be attributable to the underlying disease).</p>
<a name="i3a9520db-bd04-4239-8608-f744264b708c"></a><table>
<caption><span>Table 2: Adverse Reactions Occurring in â‰¥ 5% of Patients Receiving XIFAXAN and at a Higher Incidence Than Placebo</span></caption>
<col>
<col>
<col>
<thead>
<tr class="First">
<th class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">Â <br>
</th>
<th class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="bottom">Number (%) of Patients<br>
</th>
</tr>
<tr class="Last">
<th class="Botrule Lrule Rrule Toprule" rowspan="2" valign="bottom"><span class="Bold"><br>Â  MedDRA Preferred TermÂ Â Â </span></th>
<th class="Botrule Lrule Rrule Toprule" align="center">
<span class="Bold">XIFAXANÂ Tablets </span><br><span class="Bold">550 mgÂ TWICE</span><br><span class="Bold">DAILYÂ Â <br>N = 140</span><br>
</th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<span class="Bold"><br>Pla</span><span class="Bold">cebo<br>N = 159</span>
</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule">Â 
<p class="First">Â Â Â Â <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Edema peripheral</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">21 (15%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">13 (8%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â 
<p class="First">Â Â Â Â <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">20 (14%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">Â Â Â 21 (13%)Â Â Â </p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â 
<p class="First">Â Â Â Â <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">18 (13%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">13 (8%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â 
<p class="First">Â Â Â Â <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">17 (12%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">18 (11%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â 
<p class="First">Â Â Â Â <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">Ascites</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">16 (11%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">15 (9%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â 
<p class="First">Â Â Â Â <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle spasms</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">13 (9%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">11 (7%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â 
<p class="First">Â Â Â Â <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">13 (9%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">10 (6%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â 
<p class="First">Â Â Â Â <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">12 (9%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">13 (8%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â 
<p class="First">Â Â Â Â <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">Abdominal distension</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">11 (8%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">12 (8%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â 
<p class="First">Â Â Â Â <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> </p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">11 (8%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">6 (4%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â 
<p class="First">Â Â Â Â <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">10 (7%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">11 (7%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â 
<p class="First">Â Â Â Â <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">10 (7%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">8 (5%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â 
<p class="First">Â Â Â Â <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">10 (7%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">11 (7%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â 
<p class="First">Â Â Â Â <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">10 (7%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">10 (6%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â 
<p class="First">Â Â Â Â <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">Abdominal pain upper</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">9 (6%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">8 (5%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â 
<p class="First">Â Â Â Â <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">9 (6%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">4 (3%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â 
<p class="First">Â Â Â Â <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">9 (6%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">10 (6%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â 
<p class="First">Â Â Â Â <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">9 (6%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">10 (6%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â 
<p class="First">Â Â Â Â <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">9 (6%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">7 (4%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â 
<p class="First">Â Â Â Â <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">9 (6%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">5 (3%)</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule">Â 
<p class="First">Â Â Â Â <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">7 (5%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">6 (4%)</p>
</td>
</tr>
</tbody>
</table>
<p>Â Â Â Â Â Â Â Â The following adverse reactions, presented by body system, have also been reported in the placebo-controlled clinical trial in greater than 2% but less than 5% of patients taking XIFAXAN 550 mg taken orally two times a day for <span class="product-label-link" type="condition" conceptid="4029488" conceptname="Hepatic encephalopathy">hepatic encephalopathy</span>. The following includes adverse events occurring at a greater incidence than placebo, regardless of causal relationship to drug exposure.</p>
<p><span class="Italics">Â Â Â Â Â Â Â Â Ear and Labyrinth Disorders: </span><span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span></p>
<p><span class="Italics">Â Â Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span>: </span><span class="product-label-link" type="condition" conceptid="193322" conceptname="Right lower quadrant pain">Abdominal pain lower</span>, <span class="product-label-link" type="condition" conceptid="197981" conceptname="Abdominal tenderness">abdominal tenderness</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, esophageal variceal bleed, <span class="product-label-link" type="condition" conceptid="4152197" conceptname="Stomach ache">stomach discomfort</span></p>
<p><span class="Italics">Â Â Â Â Â Â Â Â General Disorders and Administration Site Conditions: </span><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span>, <span class="product-label-link" type="condition" conceptid="4043107" conceptname="Anasarca">generalized edema</span>, <span class="product-label-link" type="condition" conceptid="4153160" conceptname="Influenza-like symptoms">influenza like illness</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> NOS</p>
<p><span class="Italics">Â Â Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span>: </span><span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">Cellulitis</span><span class="Italics">,</span> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span> NOS</p>
<p><span class="Italics">Â Â Â Â Â Â Â Â Injury, <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">Poisoning</span> and Procedural Complications: </span><span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">Contusion</span>, <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span>, <span class="product-label-link" type="condition" conceptid="439502" conceptname="Postoperative pain">procedural pain</span></p>
<p><span class="Italics">Â Â Â Â Â Â Â Â Investigations: </span><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight increased</span></p>
<p><span class="Italics">Â Â Â Â Â Â Â Â Metabolic and Nutritional Disorders: </span><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span></p>
<p><span class="Italics">Â Â Â Â Â Â Â Â Musculoskeletal, Connective Tissue, and <span class="product-label-link" type="condition" conceptid="75909" conceptname="Disorder of bone">Bone Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span>, <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">pain in extremity</span></p>
<p><span class="Italics">Â Â Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span>: </span><span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">Amnesia</span>, <span class="product-label-link" type="condition" conceptid="4096147" conceptname="Poor concentration">disturbance in attention</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>, <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span></p>
<p><span class="Italics">Â Â Â Â Â Â Â Â Psychiatric Disorders: </span><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusional state</span></p>
<p><span class="Italics">Â Â Â Â Â Â Â Â Respiratory, Thoracic, and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span>: </span><span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span></p>
<p><span class="Italics">Â Â Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span>: </span><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_cdc36101-f824-4433-92a5-05aa2933d387"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">Â Â Â Â Â Â Â Â The
                                    following adverse reactions have been identified during post
                                    approval use of XIFAXAN.Â  Because these reactions are
                                    reported voluntarily from a population of unknown size,
                                    estimates of frequency cannot be made. Â Â These
                                    reactions have been chosen for inclusion due to either their
                                    seriousness, frequency of reporting or causal connection to
                                    XIFAXAN.Â  </p>
<p>Â Â Â Â Â Â Â Â <span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and
                                    <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span></span></span>Â  </p>
<p>Â Â Â Â Â Â Â Â Cases
                                    of <span class="Italics">C.
                                        difficile</span>-associated <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> have been
                                    reported <span class="Italics">[see Warnings and Precautions
                                                (<a href="#LINK_63662187-64c2-4919-9db0-ac306c8f84dd">5.2</a>)]</span>.</p>
<p>Â Â Â Â Â Â Â Â <span class="Italics"><span class="Underline">General</span></span></p>
<p>Â Â Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>
                                    reactions, including <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, angioneurotic
                                    <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> (<span class="product-label-link" type="condition" conceptid="4133326" conceptname="Facial swelling">swelling of face</span> and tongue and difficulty swallowing),
                                    <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> have been
                                    reported.Â  These events occurred as early as within 15
                                    minutes of drug administration.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_d6560acd-61af-4493-aa06-956bd7648379"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First"><span class="Italics">Â Â Â Â Â Â Â Â In
                                    vitro</span> studies have shown that rifaximin did
                            not inhibit cytochrome P450 isoenzymes 1A2, 2A6, 2B6, 2C9, 2C19, 2D6,
                            2E1 and CYP3A4 at concentrations ranging from 2 to 200 ng/mL <span class="Italics">[see Clinical
                                    Pharmacology (<a href="#LINK_7cafd3ea-e566-485d-879e-2864760577ad">12.3</a>)]</span>. Rifaximin is not
                            expected to inhibit these enzymes in clinical use.</p>
<p>Â Â Â Â Â Â Â Â An
                                <span class="Italics">in
                                    vitro</span> study has suggested that rifaximin
                            induces CYP3A4 <span class="Italics">[see Clinical Pharmacology (<a href="#LINK_7cafd3ea-e566-485d-879e-2864760577ad">12.3</a>)]</span>.Â  However, in
                            patients with normal liver function, rifaximin at the recommended dosing
                            regimen is not expected to induce CYP3A4.Â  It is unknown
                            whether rifaximin can have a significant effect on the pharmacokinetics
                            of concomitant CYP3A4 substrates in patients with reduced liver function
                            who have elevated rifaximin concentrations.</p>
<p>Â Â Â Â Â Â Â Â An
                                <span class="Italics">in
                                    vitro</span> study suggested that rifaximin is a
                            substrate of P-glycoprotein.Â  It is unknown whether concomitant
                            drugs that inhibit P-glycoprotein can increase the systemic exposure of
                            rifaximin <span class="Italics">[see Clinical Pharmacology (<a href="#LINK_7cafd3ea-e566-485d-879e-2864760577ad">12.3</a>)].</span>Â </p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="LINK_38ae47c5-10dd-4278-aa88-2bd5e7e50540"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_1978d785-e1b1-46b8-84c6-84003698a307"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Italics"><span class="Underline">Pregnancy Category C</span></span>Â </p>
<p>There are no adequate and well controlled studies in
                           pregnant women.Â  Rifaximin has been shown to be
                           teratogenic in rats and rabbits at doses that caused maternal
                           toxicity. XIFAXAN tablets should be used during pregnancy only
                           if the potential benefit justifies the potential risk to the
                           fetus.</p>
<p>Administration of rifaximin to pregnant rats and rabbits
                           at dose levels that caused reduced body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> resulted in
                           <span class="product-label-link" type="condition" conceptid="372424" conceptname="Congenital anomaly of eye">eye malformations</span> in both rat and rabbit fetuses. Additional
                           malformations were observed in fetal rabbits that included cleft
                           palate, lumbar <span class="product-label-link" type="condition" conceptid="72418" conceptname="Scoliosis deformity of spine">scoliosis</span>, brachygnathia, interventricular septal
                           defect, and large atrium.</p>
<p>The fetal rat malformations were observed in a study of
                           pregnant rats administered a high dose that resulted in 16 times
                           the therapeutic dose to diarrheic patients or 1 times the
                           therapeutic dose to patients with <span class="product-label-link" type="condition" conceptid="4029488" conceptname="Hepatic encephalopathy">hepatic encephalopathy</span> (based
                           upon plasma AUC comparisons).Â  Fetal rabbit
                           malformations were observed from pregnant rabbits administered
                           mid and high doses that resulted in 1 or 2 times the therapeutic
                           dose to diarrheic patients or less than 0.1 times the dose in
                           patients with <span class="product-label-link" type="condition" conceptid="4029488" conceptname="Hepatic encephalopathy">hepatic encephalopathy</span>, based upon plasma AUC
                           comparisons.</p>
<p>Post-natal developmental effects were not observed in rat
                           pups from pregnant/lactating female rats dosed during the period
                           from gestation to Day 20 post-partum at the highest dose which
                           resulted in approximately 16 times the human therapeutic dose
                           for travelersâ€™ <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (based upon AUCs) or
                           approximately 1 times the AUCs derived from therapeutic doses to
                           patients with <span class="product-label-link" type="condition" conceptid="4029488" conceptname="Hepatic encephalopathy">hepatic encephalopathy</span>.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_890b1e88-8386-45f8-81cb-e48c58ab1744"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Â Â Â Â Â Â Â Â It
                                    is not known whether rifaximin is excreted in human
                                    milk.Â  Because many drugs are excreted in human milk
                                    and because of the potential for adverse reactions in nursing
                                    infants from XIFAXAN, a decision should be made whether to
                                    discontinue nursing or to discontinue the drug, taking into
                                    account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_c82696eb-df1f-46ee-8394-8eb5d1d05ebd"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Â Â Â Â Â Â Â Â The
                                    safety and effectiveness of XIFAXAN 200 mg in pediatric patients
                                    with travelersâ€™ <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> less than 12 years of age
                                    have not been established.Â  </p>
<p>Â Â Â Â Â Â Â Â The
                                    safety and effectiveness of XIFAXAN 550 mg for HE have not been
                                    established in patients &lt; 18 years of age.</p>
<br>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="LINK_a91b2209-4424-44a5-8748-bb750c79182a"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Â Â Â Â Â Â Â Â Clinical
                                    studies with rifaximin 200 mg for travelersâ€™ <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>
                                    did not include sufficient numbers of patients aged 65 and over
                                    to determine whether they respond differently than younger
                                    subjects.Â </p>
<p>Â Â Â Â Â Â Â Â In
                                    the controlled trial with XIFAXAN 550 mg for hepatic
                                    <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>, 19.4% were 65 and over, while
                                    2.3% were 75 and over.Â  No overall differences
                                    in safety or effectiveness were observed between these subjects
                                    and younger subjects, and other reported clinical experience has
                                    not identified differences in responses between the elderly and
                                    younger patients, but greater sensitivity of some older
                                    individuals cannot be ruled out.</p>
<br>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="LINK_7c71be94-b1e1-4ab6-98c3-bbd28bfa60ca"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Â Â Â Â Â Â Â Â The
                                    pharmacokinetics of rifaximin in patients with impaired renal
                                    function has not been studied.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="LINK_e20a5a41-ac1b-4bee-8661-44551f389f05"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Â Â Â Â Â Â Â Â Following administration of XIFAXAN 550 mg twice daily to
                                    patients with a history of <span class="product-label-link" type="condition" conceptid="4029488" conceptname="Hepatic encephalopathy">hepatic encephalopathy</span>, the systemic
                                    exposure (i.e., AUC<span class="Sub">Ï„</span>) of rifaximin was about
                                    10-, 13-, and 20-fold higher in those patients with mild
                                    (Child-Pugh A), moderate (Child-Pugh B) and severe (Child-Pugh
                                    C) <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, respectively, compared to that in healthy
                                    volunteers.Â  No dosage adjustment is recommended
                                    because rifaximin is presumably acting locally.Â 
                                    Nonetheless, caution should be exercised when XIFAXAN is
                                    administered to patients with severe hepatic
                                    impairment</p>
<span class="Italics">[see Warnings and Precautions
                                            (<a href="#LINK_53c39909-6b02-4e98-8a48-dc12b43bdb37">5.4</a>), Clinical Pharmacology (<a href="#LINK_7cafd3ea-e566-485d-879e-2864760577ad">12.3</a>), Nonclinical Toxicology (<a href="#LINK_ae332060-9273-4ded-ad1a-47b8746c493c">13.2</a>), </span><span class="Italics">and Clinical Studies (<a href="#LINK_1d3a2440-6a39-4aae-bd08-e53925c4a095">14.2</a>)]</span>.
                            </div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_840f6173-6a03-44a8-8b55-240168263e5a"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Â Â Â Â Â Â Â Â No
                            specific information is available on the treatment of overdosage with
                            XIFAXAN. Â In clinical studies at doses higher than the
                            recommended dose (&gt; 600 mg/day for travelersâ€™ <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>
                            or &gt; 1100 mg/day for <span class="product-label-link" type="condition" conceptid="4029488" conceptname="Hepatic encephalopathy">hepatic encephalopathy</span>), adverse reactions
                            were similar in subjects who received doses higher than the recommended
                            dose and placebo. Â In the case of overdosage, discontinue
                            XIFAXAN, treat symptomatically, and institute supportive measures as
                            required.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_c03f9543-d811-478f-a34c-455ab9b52c55"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Â Â Â Â Â Â Â Â XIFAXAN tablets contain rifaximin, a non-aminoglycoside semi-synthetic, nonsystemic antibiotic derived from rifamycin SV. Rifaximin is a structural analog of rifampin.Â  The chemical name for rifaximin is (2<span class="Italics">S</span>,16<span class="Italics">Z</span>,18<span class="Italics">E</span>,20<span class="Italics">S</span>,21<span class="Italics">S</span>,22<span class="Italics">R</span>,23<span class="Italics">R</span>,24<span class="Italics">R</span>,25<span class="Italics">S</span>,26<span class="Italics">S</span>,27<span class="Italics">S</span>,28<span class="Italics">E</span>)-5,6,21,23,25-pentahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-2,7-(epoxypentadeca-[1,11,13]trienimino)benzofuro[4,5-e]pyrido[1,2-Ã¡]-benzimidazole-1,15(2<span class="Italics">H</span>)-dione,25-acetate. The empirical formula is C<span class="Sub">43</span>H<span class="Sub">51</span>N<span class="Sub">3</span>O<span class="Sub">11</span> and its molecular weight is 785.9.Â  The chemical structure is represented below:</p>
<div class="Figure"><img alt="Xifaxan Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=523f0320-cc73-445a-a48d-7a181c182307&amp;name=xifaxan-1.jpg"></div>
<br><br><p>Â Â Â Â Â Â Â Â XIFAXAN Tablets for oral administration are film-coated and contain 200 mg or 550 mg of rifaximin. </p>
<p>Â Â Â Â Â Â Â Â Inactive ingredients:Â  </p>
<p>Each 200 mg tablet contains colloidal silicon dioxide, disodium edetate,Â glycerol palmitostearate, hypromellose,Â microcrystalline cellulose, propylene glycol, red iron oxide, sodium starch glycolate, talc, and titanium dioxide.</p>
<p>Each 550 mg tablet contains colloidal silicon dioxide, glycerol palmitostearate, microcrystalline cellulose, polyethylene glycol/macrogol, polyvinyl alcohol, red iron oxide, sodium starch glycolate, talc,Â and titanium dioxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_d0f1b1b1-61e3-4428-bcbe-f0425596a2e6"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="LINK_82814a92-5a36-44c0-8323-5e069b61619c"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Rifaximin is an antibacterial drug <span class="Italics">[see Clinical
                                            Pharmacology (<a href="#LINK_374fa7d7-132d-43ba-986a-fcbf9b68ea93">12.4</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="LINK_7cafd3ea-e566-485d-879e-2864760577ad"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Â Â Â Â Â Â Â Â <span class="Italics"><span class="Underline">Absorption</span></span>Â </p>
<p><span class="Italics">Â Â Â Â Â Â Â Â Â Â Â Â Travelersâ€™ <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></span></p>
<p>Â Â Â Â Â Â Â Â Systemic absorption of rifaximin (200 mg three times daily) was evaluated in 13 subjects challenged with shigellosis on Days 1 and 3 of a three-day course of treatment.Â  Rifaximin plasma concentrations and exposures were low and variable. There was no evidence of accumulation of rifaximin following repeated administration for 3 days (9 doses).Â  Peak plasma rifaximin concentrations after 3 and 9 consecutive doses ranged from 0.81 to 3.4 ng/mL on Day 1 and 0.68 to 2.26 ng/mL on Day 3.Â  Similarly, AUC<span class="Sub">0-last</span> estimates were 6.95 Â± 5.15 ngâ€¢h/mL on Day 1 and 7.83 Â± 4.94 ngâ€¢h/mL on Day 3.Â  XIFAXAN is not suitable for treating systemic <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span> because of limited systemic exposure after oral administration <span class="Italics">[see Warnings and Precautions (<a href="#LINK_5b41e799-d757-48f5-b0ac-6b1fbd96c712">5.1</a>)]</span>.</p>
<p><span class="Italics">Â Â Â Â Â Â Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4029488" conceptname="Hepatic encephalopathy">Hepatic Encephalopathy</span></span></p>
<p>Â Â Â Â Â Â Â Â After a single dose and multiple doses of rifaximin 550 mg in healthy subjects, the mean time to reach peak plasma concentrations was about an hour. The pharmacokinetic (PK) parameters were highly variable and the accumulation ratio based on AUC was 1.37.</p>
<p>Â Â Â Â Â Â Â Â The PK of rifaximin in patients with a history of HE was evaluated after administration of XIFAXAN, 550 mg two times a day. The PK parameters were associated with a high variability and mean rifaximin exposure (AUC<span class="Sub">Ï„</span>) in patients with a history ofÂ HE (147 ngâ€¢h/mL) was approximately 12-fold higher than that observed in healthy subjects following the same dosing regimen (12.3 ngâ€¢h/mL).Â  When PK parameters were analyzed based on Child-Pugh Class A, B, and C, the mean AUC<span class="Sub">Ï„</span> Â was 10-, 13-, and 20-fold higher, respectively, compared to that in healthy subjects (Table 3).</p>
<a name="i5bd7d391-ee8d-4bfc-848b-f339402a6041"></a><table>
<caption><span>Table 3. Mean (Â± SD) Pharmacokinetic Parameters of Rifaximin at Steady-State in Patients with a History of <span class="product-label-link" type="condition" conceptid="4029488" conceptname="Hepatic encephalopathy">Hepatic Encephalopathy</span> by Child-Pugh Class<span class="Sup">1</span></span></caption>
<col>
<col>
<col>
<col>
<col>
<thead>
<tr class="First">
<th class="Botrule Lrule Rrule Toprule" rowspan="2">Â <br>
</th>
<th class="Botrule Lrule Rrule Toprule" rowspan="2" valign="top">
<span class="Bold">Healthy Subjects</span><br><span class="Bold">(n = 14)</span><br>
</th>
<th class="Botrule Lrule Rrule Toprule" align="center" colspan="3">
<span class="Bold">Child-Pugh Class</span><br>
</th>
</tr>
<tr class="Last">
<th class="Botrule Lrule Rrule Toprule" valign="top">
<span class="Bold">A (n = 18)</span><br>
</th>
<th class="Botrule Lrule Rrule Toprule" valign="top">
<span class="Bold">B (n = 7)</span><br>
</th>
<th class="Botrule Lrule Rrule Toprule" valign="top">
<span class="Bold">C (n = 4)</span><br>
</th>
</tr>
</thead>
<tfoot><tr class="First Last"><td>Â 
<p class="First">Â  <span class="Sup">1</span>Cross-study comparison with PK parameters in healthy subjects <br>Â  <span class="Sup">2</span>Median (range) </p>
</td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Â 
<p class="First">AUC<span class="Sub">tau</span></p>
<p>(ngâ€¢h/mL)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">12.3 Â± 4.8</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">118 Â± 67.8</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">161 Â± 101</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">246 Â± 120</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Â 
<p class="First">C<span class="Sub">max</span></p>
<p>(ng/mL)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">3.4 Â± 1.6</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">19.5 Â± 11.4</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">25.1 Â± 12.6</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">35.5 Â± 12.5</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Â 
<p class="First">T<span class="Sub">max</span><span class="Sup">2</span></p>
<p>(h)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">0.8 (0.5, 4.0)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">1 (0.9, 10)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">1 (0.97, 1)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 
<p class="First">1 (0, 2)</p>
</td>
</tr>
</tbody>
</table>
<p><span class="Italics">Â Â Â Â Â Â Â Â Food Effect in Healthy Subjects</span></p>
<p>Â Â Â Â Â Â Â Â A high-fat meal consumed 30 minutes prior to XIFAXAN dosing in healthy subjects delayed the mean time to peak plasma concentration from 0.75 to 1.5 hours and increased the systemic exposure (AUC) of rifaximin by 2-fold (Table 4).</p>
<a name="i381c04ce-eeac-4f7e-8d3f-59df05a6fc3d"></a><table>
<caption><span>Table 4. Mean (Â± SD) Pharmacokinetic Parameters After Single-Dose Â Â Â Â Â Â Administration of XIFAXAN Tablets 550 mg in Healthy Subjects Under Fasting and Fed Conditions (N = 12) </span></caption>
<col>
<col>
<col>
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" valign="top">
<span class="Bold">Parameter</span><br>
</th>
<th class="Botrule Lrule Rrule Toprule">
<span class="Bold">Fasting</span><br>
</th>
<th class="Botrule Lrule Rrule Toprule" valign="top">
<span class="Bold">Fed</span><br>
</th>
</tr></thead>
<tfoot><tr class="First Last"><td>Â 
<p class="First"><span class="Sup">1</span> Median (range)</p>
</td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top">Â 
<p class="First">C<span class="Sub">max</span> (ng/mL)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Â 
<p class="First">4.1 Â± 1.5</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Â 
<p class="First">4.8 Â± 4.3</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">Â 
<p class="First">Tmax<span class="Sup">1</span> (h)Â </p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Â 
<p class="First">0.8 (0.5, 2.1)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Â 
<p class="First">1.5 (0.5, 4.1)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">Â 
<p class="First">Half-Life (h)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Â 
<p class="First">1.8 Â± 1.4</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Â 
<p class="First">4.8 Â± 1.3</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top">Â 
<p class="First">AUC (ngâ€¢h/mL)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Â 
<p class="First">11.1 Â± 4.2</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Â 
<p class="First">22.5 Â± 12</p>
</td>
</tr>
</tbody>
</table>
<p>Â Â Â Â Â Â Â Â XIFAXAN can be administered with or without food <span class="Italics">[see Dosage and Administration (<a href="#LINK_e1e7a203-300f-4465-a6ec-6df7d9ab6c16">2.1</a> and <a href="#LINK_aeb50897-9ef2-41f7-a2d3-24daa2acd768">2.2</a>)]</span>.</p>
<p>Â Â Â Â Â Â Â Â <span class="Italics"><span class="Underline">Distribution</span></span></p>
<p>Â Â Â Â Â Â Â Â Rifaximin is moderately bound to human plasma proteins.Â  <span class="Italics">In vivo</span>, the mean protein binding ratio was 67.5% in healthy subjects and 62% in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> when XIFAXAN 550 mg was administered.</p>
<p>Â Â Â Â Â Â Â Â <span class="Italics"><span class="Underline">Metabolism and Excretion</span></span></p>
<p>Â Â Â Â Â Â Â Â In a <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> balance study, after administration of 400 mg <span class="Sup">14</span>C-rifaximin orally to healthy volunteers, of the 96.94% total recovery, 96.62% of the administered radioactivity was recovered in feces almost exclusively as the unchanged drug and 0.32% was recovered in urine mostly as metabolites with 0.03% as the unchanged drug. Rifaximin accounted for 18% of radioactivity in plasma.Â  This suggests that the absorbed rifaximin undergoes metabolism with minimal renal excretion of the unchanged drug.Â  The enzymes responsible for metabolizing rifaximin are unknown.</p>
<p>Â Â Â Â Â Â Â Â In a separate study, rifaximin was detected in the bile after cholecystectomy in patients with intact gastrointestinal mucosa, suggesting biliary excretion of rifaximin.</p>
<p>Â Â Â Â Â Â Â Â <span class="Italics"><span class="Underline">Specific Populations</span></span></p>
<p><span class="Italics">Â Â Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></p>
<p>Â Â Â Â Â Â Â Â The systemic exposure of rifaximin was markedly elevated in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> compared to healthy subjects.Â  The mean AUC in patients with Child-Pugh Class C <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> was 2-fold higher than in patients with Child-Pugh Class A <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (see Table 3), <span class="Italics">[see Warnings and Precautions (<a href="#LINK_53c39909-6b02-4e98-8a48-dc12b43bdb37">5.4</a>) and Use in Specific Populations (<a href="#LINK_e20a5a41-ac1b-4bee-8661-44551f389f05">8.7</a>)]</span>.</p>
<p><span class="Italics">Â Â Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<p>Â Â Â Â Â Â Â Â The pharmacokinetics of rifaximin in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> has not been studied.</p>
<p><span class="Italics">Â Â Â Â Â Â Â Â <span class="Underline">Drug Interactions</span></span></p>
<p><span class="Italics">Â Â Â Â Â Â Â Â In vitro</span> drug interaction studies have shown that rifaximin, at concentrations ranging from 2 to 200 ng/mL, did not inhibit human hepatic cytochrome P450 isoenzymes 1A2, 2A6, 2B6, 2C9, 2C19, 2D6, 2E1, and 3A4.Â  </p>
<p>Â Â Â Â Â Â Â Â In an<span class="Italics"> in vitro</span> study, rifaximin was shown to induce CYP3A4 at the concentration of 0.2 ÂµM.</p>
<p>Â Â Â Â Â Â Â Â An <span class="Italics">in vitro</span> study suggests that rifaximin is a substrate of P-glycoprotein.Â  In the presence of P-glycoprotein inhibitor verapamil, the efflux ratio of rifaximin was reduced greater than 50% <span class="Italics">in vitro</span>.Â  The effect of P-glycoprotein inhibition on rifaximin was not evaluated <span class="Italics">in vivo</span>.</p>
<p>Â Â Â Â Â Â Â Â The inhibitory effect of rifaximin on P-gp transporter was observed in an <span class="Italics">in vitro</span> study.Â  The effect of rifaximin on P-gp transporter was not evaluated<span class="Italics"> in vivo</span>.</p>
<p><span class="Italics">Â Â Â Â Â Â Â Â Midazolam</span></p>
<p>Â Â Â Â Â Â Â Â The effect of rifaximin 200 mg administered orally every 8 hours for 3 days and for 7 days on the pharmacokinetics of a single dose of either midazolam 2 mg intravenous or midazolam 6 mg orally was evaluated in healthy subjects. Â No significant difference was observed in the metrics of systemic exposure or elimination of intravenous or oral midazolam or its major metabolite, 1â€™-hydroxymidazolam, between midazolam alone or together with rifaximin.Â  Therefore, rifaximin was not shown to significantly affect intestinal or hepatic CYP3A4 activity for the 200 mg three times a day dosing regimen.</p>
<p>Â Â Â Â Â Â Â Â After XIFAXAN 550 mg was administered three times a day for 7 days and 14 days to healthy subjects, the mean AUC of single midazolam 2 mg orally was 3.8% and 8.8% lower, respectively, than when midazolam was administered alone.Â  The mean C<span class="Sub">max</span> of midazolam was also decreased by 4-5% when XIFAXAN was administered for 7-14 days prior to midazolam administration.Â  This degree of interaction is not considered clinically meaningful.</p>
<p>Â Â Â Â Â Â Â Â The effect of rifaximin on CYP3A4 in patients with <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">impaired liver function</span> who have elevated systemic exposure is not known.</p>
<p><span class="Italics">Â Â Â Â Â Â Â Â Oral Contraceptives Containing 0.07 mg Ethinyl Estradiol and 0.5 mg Norgestimate</span></p>
<p>Â Â Â Â Â Â Â Â The oral contraceptive study utilized an open-label, crossover design in 28 healthy female subjects to determine if rifaximin 200 mg orally administered three times a day for 3 days (the dosing regimen for travelersâ€™ <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>) altered the pharmacokinetics of a single dose of an oral contraceptive containing 0.07 mg ethinyl estradiol and 0.5 mg norgestimate.Â  Results showed that the pharmacokinetics of single doses of ethinyl estradiol and norgestimate were not altered by rifaximin <span class="Italics">[see</span>Â <span class="Italics">Drug Interactions (<a href="#LINK_d6560acd-61af-4493-aa06-956bd7648379">7</a>)]</span>.</p>
<p>Â Â Â Â Â Â Â Â Effect of rifaximin on oral contraceptives was not studied for XIFAXAN 550 mg twice a day, the dosing regimen for <span class="product-label-link" type="condition" conceptid="4029488" conceptname="Hepatic encephalopathy">hepatic encephalopathy</span>.Â </p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_374fa7d7-132d-43ba-986a-fcbf9b68ea93"></a><a name="section-11.3"></a><p></p>
<h2>12.4 Microbiology</h2>
<p class="First">Â Â Â Â Â Â Â Â <span class="Italics"><span class="Underline">Mechanism of Action</span></span></p>
<p>Â Â Â Â Â Â Â Â Rifaximin
                                    is a non-aminoglycoside semi-synthetic antibacterial derived
                                    from rifamycin SV.Â  Rifaximin acts by binding to the
                                    beta-subunit of bacterial DNA-dependent RNA polymerase resulting
                                    in inhibition of bacterial RNA synthesis.</p>
<p><span class="Italics">Â Â Â Â Â Â Â Â Escherichia
                                            coli </span>has been shown to develop
                                    resistance to rifaximin <span class="Italics">in
                                    vitro</span>.Â  However, the clinical
                                    significance of such an effect has not been studied.Â  </p>
<p>Â Â Â Â Â Â Â Â Rifaximin
                                    is a structural analog of rifampin. Organisms with high
                                    rifaximin <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentration</span> (MIC) values also
                                    have elevated MIC values against rifampin. Cross-resistance
                                    between rifaximin and other classes of antimicrobials has not
                                    been studied.Â  </p>
<p>Â Â Â Â Â Â Â Â Rifaximin
                                    has been shown to be active against the following pathogen in
                                    clinical studies of <span class="product-label-link" type="condition" conceptid="197484" conceptname="Diarrhea of presumed infectious origin">infectious diarrhea</span> as described in the
                                        <span class="Italics">Indications and Usage (<a href="#LINK_dfbc66a2-cbe8-498e-a7e6-1688402aad30">1</a>) </span>section: <span class="Italics">Escherichia coli </span>(enterotoxigenic
                                    and enteroaggregative <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>).</p>
<p>Â Â Â Â Â Â Â Â For
                                    HE, rifaximin is thought to have an effect on the
                                    gastrointestinal flora.</p>
<p>Â Â Â Â Â Â Â Â <span class="Italics"><span class="Underline">Susceptibility Tests</span></span></p>
<p><span class="Italics">Â Â Â Â Â Â Â Â In
                                            vitro </span>susceptibility testing was
                                    performed according to the National Committee for Clinical
                                    Laboratory Standards (NCCLS) agar dilution method M7-A6 <span class="Italics">[see
                                            References (<a href="#LINK_e9505da9-d318-46d8-9368-d251e02ab535">15</a>)]</span>. However, the
                                    correlation between susceptibility testing and clinical outcome
                                    has not been determined.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="LINK_c366dc1a-aac9-484f-bca5-074a4d13a29d"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_efb5c1d2-1a38-46e3-951a-3715b74b15c1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Â Â Â Â Â Â Â Â Malignant
                                    schwannomas in the heart were significantly increased in male
                                    Crl:CDÂ® (SD) rats that received rifaximin by oral
                                    gavage for two years at 150 to 250 mg/kg/day (doses equivalent
                                    to 2.4 to 4 times the recommended dose of 200 mg three times
                                    daily for travelersâ€™ <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and equivalent to 1.3
                                    to 2.2 times the recommended dose of 550 mg twice daily for
                                    <span class="product-label-link" type="condition" conceptid="4029488" conceptname="Hepatic encephalopathy">hepatic encephalopathy</span>, based on relative body surface area
                                    comparisons).Â  There was no increase in tumors in
                                    Tg.rasH2 mice dosed orally with rifaximin for 26 weeks at 150 to
                                    2000 mg/kg/day (doses equivalent to 1.2 to 16 times the
                                    recommended daily dose for travelersâ€™ <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and
                                    equivalent to 0.7 to 9 times the recommended daily dose for
                                    <span class="product-label-link" type="condition" conceptid="4029488" conceptname="Hepatic encephalopathy">hepatic encephalopathy</span>, based on relative body surface area
                                    comparisons).</p>
<p>Â Â Â Â Â Â Â Â Rifaximin
                                    was not genotoxic in the bacterial reverse mutation assay,
                                    chromosomal aberration assay, rat bone marrow micronucleus
                                    assay, rat hepatocyte unscheduled DNA synthesis assay, or the
                                    CHO/HGPRT mutation assay. Â There was no effect on
                                    fertility in male or female rats following the administration of
                                    rifaximin at doses up to 300Â mg/kg (approximately 5
                                    times the clinical dose of 600 mg/day, and approximately 2.6
                                    times the clinical dose of 1100 mg/day, adjusted for body
                                    surface area).</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="LINK_ae332060-9273-4ded-ad1a-47b8746c493c"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology</h2>
<p class="First">Â Â Â Â Â Â Â Â Oral administration of rifaximin for 3-6 months produced
                                    hepatic proliferation of connective tissue in rats (50
                                    mg/kg/day) and fatty degeneration of liver in dogs (100
                                    mg/kg/day).Â  However, plasma drug levels were not
                                    measured in these studies. Subsequently, rifaximin was studied
                                    at doses as high as 300 mg/kg/day in rats for 6 months and 1000
                                    mg/kg/day in dogs for 9 months, and no signs of hepatotoxicity
                                    were observed. The maximum plasma AUC
                                <span class="Sub">0-8 hrÂ </span>
                                values from the 6 month rat and 9 month dog toxicity
                                    studies (range: 42-127 ngâ€¢h/mL) was lower than the
                                    maximum plasma AUC
                                <span class="Sub">0-8 hr </span>
                                values in cirrhotic patients (range: 19-306
                                    ngâ€¢h/mL).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="LINK_7cfacc9f-9444-4f1f-b57c-fccb367c3cbc"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="34092-7">
<a name="LINK_fd945abe-1e7a-44d6-ab02-a58cb344efef"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Travelersâ€™ <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></h2>
<p class="First">Â Â Â Â Â Â Â Â The
                                    efficacy of XIFAXAN given as 200 mg orally taken three times a
                                    day for 3 days was evaluated in 2 randomized,
                                    multiâ€‘center, double-blind, placebo-controlled studies
                                    in adult subjects with travelersâ€™ <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.
                                    Â One study was conducted at clinical sites in Mexico,
                                    Guatemala, and Kenya (Study 1). Â The other study was
                                    conducted in Mexico, Guatemala, Peru, and India (Study
                                    2).Â  Stool specimens were collected before treatment
                                    and 1 to 3 days following the end of treatment to identify
                                    enteric pathogens. Â The predominant pathogen in both
                                    studies was <span class="Italics">Escherichia
                                        coli</span>.</p>
<p>Â Â Â Â Â Â Â Â The
                                    clinical efficacy of XIFAXAN was assessed by the time to return
                                    to normal, formed stools and resolution of symptoms.Â 
                                    The primary efficacy endpoint was time to last unformed stool
                                    (TLUS) which was defined as the time to the last unformed stool
                                    passed, after which clinical cure was declared. Â Table
                                    5 displays the median TLUS and the number of patients who
                                    achieved clinical cure for the intent to treat (ITT) population
                                    of Study 1.Â  The duration of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> was significantly
                                    shorter in patients treated with XIFAXAN than in the placebo
                                    group. More patients treated with XIFAXAN were classified as
                                    clinical cures than were those in the placebo group.</p>
<br><a name="iaf91170e-b0a3-4128-8aa7-6072bac4cc4a"></a><table>
<caption><span>Table 5. Clinical Response in Study 1 (ITT
                                        population)</span></caption>
<col>
<col>
<col>
<col>
<col>
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="center"> Â </th>
<th class="Botrule Lrule Rrule Toprule" align="center">
<span class="Bold">Â XIFAXANÂ </span><br><span class="Bold">(n=</span><span class="Bold">125)</span>Â </th>
<th class="Botrule Lrule Rrule Toprule">
<span class="Bold">Â PlaceboÂ </span><br><span class="Bold">(n=</span><span class="Bold">129)</span>
</th>
<th class="Botrule Lrule Rrule Toprule" align="center">
<span class="Bold">Estimate</span><br><span class="Bold">Â (97.5% CI)Â </span>
</th>
<th class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold"><br>
                                                  Â P-ValueÂ </span></th>
</tr></thead>
<tfoot><tr class="First Last"><td>Â <p class="First">Â Â Â Â Â Â Â Â Â 
                                                <span class="Sup">a</span> Hazard Ratio <br>Â Â Â Â Â Â Â Â Â 
                                                <span class="Sup">b</span> Difference in rates
                                            </p>
</td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center">Â Median TLUS<br> (hours)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 32.5 </td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 58.6</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â <p class="First">1.78<span class="Sup">a</span></p>
                                                (1.26, 2.50)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 0.0002</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center">Â Â Clinical cure,
                                                nÂ <br> (%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â Â 99 (79.2)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â Â 78 (60.5)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â Â  18.7<span class="Sup">b</span><br> (5.3,
                                                32.1)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 0.001</td>
</tr>
</tbody>
</table>
<p>Â Â Â Â Â Â Â Â Microbiological
                                    eradication (defined as the absence of a baseline pathogen in
                                    culture of stool after 72 hours of therapy) rates for Study 1
                                    are presented in TableÂ 6 for patients with any pathogen
                                    at baseline and for the subset of patients with <span class="Italics">Escherichia coli</span> at
                                    baseline.Â  <span class="Italics">Escherichia
                                        coli</span> was the only pathogen with
                                    sufficient numbers to allow comparisons between treatment
                                    groups.</p>
<p>Â Â Â Â Â Â Â Â Even
                                    though XIFAXAN had microbiologic activity similar to placebo, it
                                    demonstrated a clinically significant reduction in duration of
                                    <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and a higher clinical cure rate than placebo.Â 
                                    Therefore, patients should be managed based on clinical response
                                    to therapy rather than microbiologic response.</p>
<br><a name="i211eabc6-973f-49c7-89e8-b93547cbbf88"></a><table>
<caption><span>Table 6. Microbiologic Eradication Rates in Study 1
                                        Subjects with a Baseline Pathogen </span></caption>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule">Â Â </td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â <span class="Bold"><span class="Bold">XIFAXAN</span>Â </span>Â </td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â <span class="Bold">Placebo</span>Â </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â OverallÂ </td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 48/70 (68.6)Â </td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 41/61 (67.2)Â </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule">Â <span class="Italics">E.
                                                coli</span>Â </td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 38/53 (71.7)Â </td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 40/54 (74.1)Â </td>
</tr>
</tbody>
</table>
<br><p>Â Â Â Â Â Â Â Â The
                                    results of Study 2 supported the results presented for Study 1.
                                    Â In addition, this study provided evidence that
                                    subjects treated with XIFAXAN with <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and/or blood in the
                                    stool at baseline had prolonged TLUS. Â These subjects
                                    had lower clinical cure rates than those without <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or blood
                                    in the stool at baseline. Â Many of the patients with
                                    <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and/or blood in the stool (<span class="product-label-link" type="condition" conceptid="4008089" conceptname="Dysentery">dysentery</span>-like diarrheal
                                    syndromes) had invasive pathogens, primarily <span class="Italics">Campylobacter jejuni</span>, isolated in
                                    the baseline stool.</p>
<p>Â Â Â Â Â Â Â Â Also
                                    in this study, the majority of the subjects treated with XIFAXAN
                                    who had <span class="Italics">Campylobacter jejuni
                                        </span>isolated as a sole pathogen at baseline
                                    failed treatment and the resulting clinical cure rate for these
                                    patients was 23.5% (4/17). Â In addition to not
                                    being different from placebo, the microbiologic eradication
                                    rates for subjects with <span class="Italics">Campylobacter jejuni
                                        </span>isolated at baseline were much lower
                                    than the eradication rates seen for <span class="Italics">Escherichia
                                            coli</span>.Â  </p>
<p>Â Â Â Â Â Â Â Â In
                                    an unrelated open-label, pharmacokinetic study of oral XIFAXAN
                                    200 mg taken every 8 hours for 3 days, 15 adult subjects were
                                    challenged with <span class="Italics">Shigella flexneri
                                        </span>2a, of whom 13 developed <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> or
                                    <span class="product-label-link" type="condition" conceptid="4008089" conceptname="Dysentery">dysentery</span> and were treated with XIFAXAN. Â Although this
                                    open-label challenge trial was not adequate to assess the
                                    effectiveness of XIFAXAN in the treatment of shigellosis, the
                                    following observations were noted: eight subjects received
                                    rescue treatment with ciprofloxacin either because of lack of
                                    response to XIFAXAN treatment within 24 hours (2), or because
                                    they developed severe <span class="product-label-link" type="condition" conceptid="4008089" conceptname="Dysentery">dysentery</span> (5), or because of recurrence of
                                        <span class="Italics">Shigella flexneri </span>in the stool (1);
                                    five of the 13 subjects received ciprofloxacin although they did
                                    not have evidence of severe disease or relapse.</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="LINK_1d3a2440-6a39-4aae-bd08-e53925c4a095"></a><a name="section-13.2"></a><p></p>
<h2>14.2 <span class="product-label-link" type="condition" conceptid="4029488" conceptname="Hepatic encephalopathy">Hepatic Encephalopathy</span></h2>
<p class="First">Â Â Â Â Â Â Â Â The
                                    efficacy of XIFAXAN 550 mg taken orally two times a day was
                                    evaluated in a randomized, placebo-controlled, double-blind,
                                    multi-center 6-month trial of adult subjects from the U.S.,
                                    Canada and Russia who were defined as being in remission (Conn
                                    score of 0 or 1) from <span class="product-label-link" type="condition" conceptid="4029488" conceptname="Hepatic encephalopathy">hepatic encephalopathy</span> (HE).Â 
                                    Eligible subjects hadÂ â‰¥ 2 episodes of HE
                                    associated with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">chronic liver disease</span> in the previous 6
                                    months.Â Â  </p>
<p>Â Â Â Â Â Â Â Â A
                                    total of 299 subjects were randomized to receive either XIFAXAN
                                    (n=140) or placebo (n=159) in this study. Â Patients had
                                    a mean age of 56 years (range, 21-82 years), 81%
                                    &lt; 65 years of age, 61% were male and 86%
                                    White. Â At baseline, 67% of patients had a Conn
                                    score of 0 and 68% had an <span class="product-label-link" type="condition" conceptid="4138992" conceptname="Asterixis">asterixis</span> grade of 0.
                                    Â Patients had MELD scores of
                                    eitherÂ â‰¤ 10 (27%) or 11 to 18
                                    (64%) at baseline. No patients were enrolled with a MELD
                                    score of &gt; 25.Â  Nine percent of the patients
                                    were Child-Pugh Class C.Â  Lactulose was concomitantly
                                    used by 91% of the patients in each treatment arm of the
                                    study.Â  Per the study protocol, patients were withdrawn
                                    from the study after experiencing a breakthrough HE
                                    episode.Â  Other reasons for early study discontinuation
                                    included: adverse reactions (XIFAXAN 6%; placebo
                                    4%), patient request to withdraw (XIFAXAN 4%;
                                    placebo 6%) and other (XIFAXAN 7%; placebo
                                    5%).Â Â  </p>
<p>Â Â Â Â Â Â Â Â The
                                    primary endpoint was the time to first breakthrough overt HE
                                    episode.Â  A breakthrough overt HE episode was defined
                                    as a marked deterioration in neurological function and an
                                    increase of Conn score to Grade â‰¥ 2.Â  In
                                    patients with a baseline Conn score of 0, a breakthrough overt
                                    HE episode was defined as an increase in Conn score of 1 and
                                    <span class="product-label-link" type="condition" conceptid="4138992" conceptname="Asterixis">asterixis</span> grade of 1.Â  </p>
<p>Â Â Â Â Â Â Â Â Breakthrough
                                    overt HE episodes were experienced by 31 of 140 subjects
                                    (22%) in the XIFAXAN group and by 73 of 159 subjects
                                    (46%) in the placebo group during the 6-month treatment
                                    period.Â  Comparison of Kaplan-Meier estimates of
                                    event-free curves showed XIFAXAN significantly reduced the risk
                                    of HE breakthrough by 58% during the 6-month treatment
                                    period.Â  Presented below in Figure 1 is the
                                    Kaplan-Meier event-free curve for all subjects (n = 299) in the
                                    study.</p>
<p><span class="Bold">Figure 1: Kaplan-Meier
                                            Event-Free Curves<span class="Sup">1</span> in HE Study (Time to First <br>
                                            Breakthrough-HE Episode up to 6 Months of Treatment, Day
                                            170) (ITT<br> Population)</span></p>
<br><p><img alt="Kaplan-Meier Event-Free Curves Graph" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=523f0320-cc73-445a-a48d-7a181c182307&amp;name=xifaxan-2.jpg"><br><span class="Sub">Â Â Â Â Â Â Â Â Â Â Note:Â Open
                                        diamonds and open triangles represent censored
                                        subjects.</span><br>Â Â Â Â Â Â Â Â Â 
                                    <span class="Sup">1</span><span class="Sub">Event-free
                                        refers to non-occurrence of breakthrough HE.</span></p>
<p>Â Â Â Â Â Â Â Â When
                                    the results were evaluated by the following demographic and
                                    baseline characteristics, the treatment effect of XIFAXAN 550 mg
                                    in reducing the risk of breakthrough overt HE recurrence was
                                    consistent for: sex, baseline Conn score, duration of current
                                    remission and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. The differences in treatment effect
                                    could not be assessed in the following subpopulations due to
                                    small sample size: non-White (n=42), baseline MELD &gt; 19
                                    (n=26), Child-Pugh C (n=31), and those without concomitant
                                    lactulose use (n=26).</p>
<p>Â Â Â Â Â Â Â Â HE-related hospitalizations (hospitalizations directly
                                    resulting from HE, or hospitalizations complicated by HE) were
                                    reported for 19 of 140 subjects (14%) and 36 of 159
                                    subjects (23%) in the XIFAXAN and placebo groups
                                    respectively. Comparison of Kaplan-Meier estimates of event-free
                                    curves showed XIFAXAN significantly reduced the risk of
                                    HE-related hospitalizations by 50% during the 6-month
                                    treatment period. Comparison of Kaplan-Meier estimates of
                                    event-free curves is shown in Figure 2.</p>
<p><span class="Bold">Figure 2:Â 
                                            Kaplan-Meier Event-Free Curves<span class="Sup">1</span> in Pivotal HE
                                            Study (Time<br> to First HE-Related Hospitalization in HE
                                            Study up to 6 Months of<br> Treatment, Day 170) (ITT
                                            Population)Â <br></span></p>
<div class="Figure"><img alt="Kaplan-Meier Event-Free Curves_PivotalHEStudy" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=523f0320-cc73-445a-a48d-7a181c182307&amp;name=xifaxan-3.jpg"></div>
<p>Â Â Â Â Â Â Â Â Â Â 
                                        <span class="Sub">Note:Â Open diamonds and open triangles
                                        represent censored subjects.</span><br>
                                        Â Â Â Â Â Â Â Â Â Â <span class="Sup">1</span><span class="Sub">Event-free refers to non-occurrence of HE-related
                                        hospitalization.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="LINK_e9505da9-d318-46d8-9368-d251e02ab535"></a><a name="section-14"></a><p></p>
<h1>15 REFERENCES</h1>
<p class="First">Â Â Â Â Â Â Â Â Methods for dilution antimicrobial susceptibility tests for
                            bacteria that grow aerobically. National Committee for Clinical
                            Laboratory Standards, Sixth Edition, Wayne PA.
                        <span class="Italics">Approved Standard NCCLS Document M7-A6
                            </span>
                       January 2003; 23 (2).</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_14cc8621-7f38-4bab-af4c-383f3ebed8aa"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_191cae51-7beb-4cb7-b293-b7eceb443a72"></a><a name="section-15.1"></a><p></p>
<h2></h2>
<p class="First">Â Â Â Â Â Â Â Â  200 mg tablet is a pink-colored, round, biconvex tablet with â€œSxâ€? debossed on one side.Â  It is available in the following presentations: </p>
<ul class="Disk">
<li>NDC 54868-5972-1, bottles of 03 tablets 
</li>
<li>NDC 54868-5972-2, bottles of 09 tablets
</li>
<li>NDC 54868-5972-0, bottles of 30 tablets</li>
</ul>
<p>Â Â Â Â Â Â Â Â The 550 mg tablet is a pink-colored, oval, biconvex tablet with â€œrfxâ€? debossed on one side.Â  It is available in the following presentations:</p>
<ul class="Disk">
<li>NDC 54868-6154-0, bottles of 02 tablets 
</li>
<li>NDC 54868-6154-1, bottles of 09 tablets
</li>
<li>NDC 54868-6154-2, bottles of 10 tablets</li>
</ul>
<p><span class="Bold">Storage</span></p>
<p>Â Â Â Â Â Â Â Â Store XIFAXAN Tablets at 20â€“25Â°C (68â€“77Â°F); excursions permitted to 15â€“30Â°C (59-86Â°F). See USP Controlled Room Temperature.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_f9bf6cd0-7696-4915-9ea6-dc538eaea5ae"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_73a41744-d945-4596-b945-6c62197dd605"></a><a name="section-16.1"></a><p></p>
<h2>17.1 Persistent <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></h2>
<p class="First">Â Â Â Â Â Â Â Â For
                                    those patients being treated for travelersâ€™ <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>,
                                    discontinue XIFAXAN if <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> persists more than 24-48 hours
                                    or worsens. Advise the patient to seek medical care for <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>
                                    and/or blood in the stool [see <span class="Italics">Warnings and Precautions
                                                (<a href="#LINK_5b41e799-d757-48f5-b0ac-6b1fbd96c712">5.1</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_e22e09b6-07f3-457b-8daf-23456626f126"></a><a name="section-16.2"></a><p></p>
<h2>17.2 <span class="Italics">Clostridium difficile</span>-Associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></h2>
<p class="First"><span class="Italics">Â Â Â Â Â Â Â Â Clostridium
                                            difficile</span>-associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD)
                                    has been reported with use of nearly all antibacterial agents,
                                    including XIFAXAN, and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>
                                    to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.Â  Treatment with antibiotics alters
                                    the normal flora of the colon which may lead to <span class="Italics">C.
                                            difficile</span>.Â  Patients can
                                    develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span>
                                    and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as two or more months after having taken
                                    the last dose of the antibiotic.Â  If <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> occurs
                                    after therapy or does not improve or worsens during therapy,
                                    advise patients to contact a physician as soon as possible [see
                                        <span class="Italics">Warnings and Precautions (<a href="#LINK_53c39909-6b02-4e98-8a48-dc12b43bdb37">5.4</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_598a0bc7-e465-41c1-a951-6481a2c474e4"></a><a name="section-16.3"></a><p></p>
<h2>17.3 Administration with Food</h2>
<p class="First">Â Â Â Â Â Â Â Â Inform
                                    patients that XIFAXAN may be taken with or without
                                    food.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_bbe61575-be35-4811-a1a3-649a943dc3b1"></a><a name="section-16.4"></a><p></p>
<h2>17.4 Antibacterial Resistance</h2>
<p class="First">Â Â Â Â Â Â Â Â Counsel
                                    patients that antibacterial drugs including XIFAXAN should only
                                    be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. Â They do not
                                    treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>).Â  When
                                    XIFAXAN is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients
                                    should be told that although it is common to feel better early
                                    in the course of therapy, the medication should be taken exactly
                                    as directed.Â  Skipping doses or not completing the full
                                    course of therapy may (1) decrease the effectiveness of the
                                    immediate treatment and (2) increase the likelihood that
                                    bacteria will develop resistance and will not be treatable by
                                    XIFAXAN or other antibacterial drugs in the future.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_f611ad67-4329-4851-8d5f-f84d508222e9"></a><a name="section-16.5"></a><p></p>
<h2>17.5 Severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Â Â Â Â Â Â Â Â Patients should be informed that in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh C) there is an increase in systemic exposure to XIFAXAN <span class="Italics">[see Warnings and Precautions (<a href="#LINK_53c39909-6b02-4e98-8a48-dc12b43bdb37">5.4</a>)]</span>.</p>
<p>Manufactured for:</p>
<div class="Figure">
<img alt="salix-logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=523f0320-cc73-445a-a48d-7a181c182307&amp;name=xifaxan-4.jpg"><p class="MultiMediaCaption"></p>
</div>
<p>Salix Pharmaceuticals, Inc. </p>
<p>Raleigh, NC 27615</p>
<p>XIFAXAN<span class="Sup">Â®</span> is a trademark of Salix Pharmaceuticals, Inc., under license from Alfa Wassermann S.p.A.<br>Copyright Â© Salix Pharmaceuticals, Inc.</p>
<p>Rifaximin for Travelers' <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> and <span class="product-label-link" type="condition" conceptid="4029488" conceptname="Hepatic encephalopathy">Hepatic encephalopathy</span> is protected by US Patent Nos. 7,045,620; 7,612,199; 7,902,206 and 7,906,542. Rifaximin for Travelers' <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is also protected by US Patent No. 7,928,115.</p>
<p>Web site: <a href="#www.Salix.com">www.Salix.com</a></p>
<p>All rights reserved.</p>
<p>VENART-156-2</p>
<p>OCT 2011</p>
<p>Relabeling and Repackaging by:</p>
<p>Physicians Total Care, Inc. </p>
<p>Tulsa, Oklahoma   74146</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_1a69ffcd-7a3c-489d-bce6-434552b3d80c"></a><a name="section-17"></a><p></p>
<h1>PACKAGE LABEL - PRINCIPAL DISPLAY</h1>
<p class="First"><span class="Bold">PACKAGE LABEL â€“ PRINCIPAL DISPLAY â€“ XIFAXAN 200 mg TabletsÂ Â   <br></span></p>
<p><span class="Bold"></span><br></p>
<p><span class="Bold">Xifaxan<span class="Sup">Â®</span></span><br>(rifaxamin) tablets 200 mg </p>
<p>Rx only</p>
<div class="Figure"><img alt="XIFAXAN 200 mg Tablets Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=523f0320-cc73-445a-a48d-7a181c182307&amp;name=5972.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_16d0c64d-add6-418f-a2b4-360f32c8b3a6"></a><a name="section-18"></a><p></p>
<h1>PACKAGE LABEL - PRINCIPAL DISPLAY</h1>
<p class="First"><span class="Bold">PACKAGE LABEL â€“ PRINCIPAL DISPLAY â€“ XIFAXANÂ 550 mgÂ TabletsÂ Â   <br></span></p>
<p><span class="Bold"></span><br></p>
<p><span class="Bold">Xifaxan<span class="Sup">Â®</span></span><br>(rifaximin) 550 mg tablets</p>
<p><br></p>
<p>Rx ONLY</p>
<div class="Figure"><img alt="XIFAXAN 550 mg Tablets Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=523f0320-cc73-445a-a48d-7a181c182307&amp;name=6154.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>XIFAXANÂ 		
					</strong><br><span class="contentTableReg">rifaximin tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5972(NDC:65649-301)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>RIFAXIMIN</strong> (RIFAXIMIN) </td>
<td class="formItem">RIFAXIMIN</td>
<td class="formItem">200Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>EDETATE DISODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GLYCERYL PALMITOSTEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK (PINK) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (BICONVEX) </td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Sx</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5972-0</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-5972-1</td>
<td class="formItem">3  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:54868-5972-2</td>
<td class="formItem">9  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021361</td>
<td class="formItem">12/14/2008</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>XIFAXANÂ 		
					</strong><br><span class="contentTableReg">rifaximin tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-6154(NDC:65649-303)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>RIFAXIMIN</strong> (RIFAXIMIN) </td>
<td class="formItem">RIFAXIMIN</td>
<td class="formItem">550Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>EDETATE DISODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GLYCERYL PALMITOSTEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK (PINK) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (OVAL) </td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">rfx</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-6154-0</td>
<td class="formItem">2  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-6154-1</td>
<td class="formItem">9  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:54868-6154-2</td>
<td class="formItem">10  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022554</td>
<td class="formItem">08/19/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel, repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>75eebf07-eadb-4b8d-b67c-a5a5780dcfdf</div>
<div>Set id: 523f0320-cc73-445a-a48d-7a181c182307</div>
<div>Version: 2</div>
<div>Effective Time: 20111228</div>
</div>
</div>Â <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
